Clinuvel Pharmaceuticals (ASX:CUV)
ASX announcement history & article coverage
Transparent by design.
Announcments by Clinuvel Pharmaceuticals (ASX:CUV) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
SCENESSE approved for EPP in Canada
Health Canada approves SCENESSE® for EPP treatment, expanding CLINUVEL's market
CLINUVEL confirms terms of CEO's Employment Agreement
CLINUVEL publicly files 20-F to U.S. SEC
CLINUVEL files 20-F with SEC to pursue Nasdaq ADS listing upgrade
CLINUVEL US Non-Deal Roadshow Presentation
Notification regarding unquoted securities - CUV
CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
Clinuvel Advances Nasdaq ADR Level II Uplisting with SEC Review Ongoing
FDA relaxes SCENESSE postmarketing requirement
FDA drops cardiac QT study requirement for SCENESSE®, confirming strong safety profile
Final EMA scientific advice for pivotal Phase III vitiligo
CLINUVEL secures EMA scientific advice for pivotal Phase III vitiligo study with SCENESSE®
Notification of cessation of securities - CUV